企業プロフィール
FEMASYS 株価・ニュース・カタリスト
- ティッカー:
- FEMY
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
2.10 USD (-2.78%)
終値
最終更新: 2026年10月1日
22.4M USD
時価総額
株価変動の要因
2026年10月1日 時点で FEMY は 2.78% 下落し、$2.10 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Women's Health Medical Device Company
Femasys develops office-based products for reproductive health. Its portfolio addresses permanent contraception, infertility treatment, and diagnostic evaluation of the uterus and fallopian tubes.
FemBloc Permanent Contraception
FemBloc is a non-surgical permanent birth-control system delivered through the fallopian tubes in a physician's office. The product is designed to avoid surgical incisions, general anesthesia, and implanted metal devices.
FINALE Pivotal Program
The FINALE study is the final stage of the U.S. pivotal clinical program for FemBloc. The trial is intended to provide the effectiveness and safety evidence needed for a future FDA submission.
FemaSeed Fertility Treatment
FemaSeed delivers sperm directly into a selected fallopian tube, closer to the site of fertilization than standard intrauterine insemination. It is positioned as an office-based option before more invasive assisted-reproduction procedures.
Diagnostic Product Portfolio
FemVue and FemCath products help physicians evaluate fallopian-tube patency and the uterine cavity. These commercial devices provide an established channel with obstetricians, gynecologists, and fertility specialists.
今後のカタリスト
- Completion of the pivotal FINALE study of FemBloc to support a future U.S. regulatory submission.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。